A therapy that retrains the body’s immune system to fight cancer has provoked excitement after more than 90% of terminally ill patients reportedly went into remission.
White blood cells were taken from patients with leukaemia, modified in the lab and then put back.
But the data has not been published or reviewed and two patients are said to have died from an extreme immune response.
Experts said the trial was exciting, but still only “a baby step.”
The news bubbled out of the American Association for the Advancement of Science’s annual meeting in Washington DC.
The lead scientist, Prof Stanley Riddell from the Fred Hutchinson Cancer Research Centre in Seattle, said all other treatments had failed in these patients and they had only two-to-five months to live.
He told the conference that: “The early data is unprecedented.”
In the trial, cells from the immune system called killer t-cells were taken out of dozens of patients. The cells normally act like bombs destroying infected tissue.
The researchers genetically modified the t-cells to engineer a new targeting mechanism – with the technical name of chimeric antigen receptors – to target acute lymphoblastic leukaemia.
Prof Riddell told the BBC: “Essentially what this process does is, it genetically reprograms the T-cell to seek out and recognise and destroy the patient’s tumour cells.
“[The patients] were really at the end of the line in terms of treatment options and yet a single dose of this therapy put more than ninety percent of these patients in complete remission where we can’t detect any of these leukaemia cells.”
But one cancer expert told me they still felt in the dark on the full significance of the study, as the data is not available.
Learn more: Excitement at new cancer treatment
The Latest on: Cancer immunotherapy
via Google News
The Latest on: Cancer immunotherapy
- Conflicting data reported on immunotherapy benefit for older NSCLC patients on April 17, 2019 at 10:01 am
medwireNews: The overall survival (OS) benefit of immunotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC) is unclear according to two studies with contradictory results ... […]
- OncoSec and Duke Announce New Collaboration in Cancer Research on April 17, 2019 at 9:46 am
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body’s immune system to target and attack cancer. OncoSec’s lead ... […]
- Immunotherapy Drugs Market is Anticipated to Cross US$ 289.52 Billion by 2024 on April 17, 2019 at 7:00 am
Apr 17, 2019 (Heraldkeeper via COMTEX) -- New York, April 17, 2019: Immunotherapy refers to treatments that stimulate, beautify or suppress the body’s personal immune system. Cancer segment is ... […]
- Iteos advancing adenosine antagonist as cancer immunotherapy in phase I/Ib on April 16, 2019 at 9:18 pm
LONDON - Iteos Therapeutics SA has joined the growing band of companies seeking to reverse tumor immune evasion by blocking the anti-inflammatory effects of adenosine signaling, with dosing of the ... […]
- UCSD patient gets first cancer treatment made from stem cells on April 16, 2019 at 7:58 am
A new form of cancer immunotherapy has been given to a University of California, San Diego Health patient in the first test of immune cells grown from stem cells. The patient, Derek Ruff ... […]
- Cancer Immunotherapy Market to attain a value of US$124.88 billion by 2024 - TMR on April 15, 2019 at 5:15 am
Albany, NY, Apr 15, 2019 (GLOBE NEWSWIRE via COMTEX) -- Albany, NY, April 15, 2019 (GLOBE NEWSWIRE) -- According to TMR, the global cancer immunotherapy market is estimated to expand at a CAGR of 14.6 ... […]
- Cancer cells use tactics to avoid being recognised by immunotherapy agents on April 14, 2019 at 11:53 pm
Researchers have found that bowel cancer cells have a mechanism by which they can switch off some key molecules on their surfaces and thus escape being recognised and killed by the immunotherapy ... […]
- New Target for Cancer Immunotherapy: Exosomes on April 9, 2019 at 6:08 am
It was once a central tenet of biology that RNA molecules did their work inside the cell. But it’s now clear that RNA molecules are also active outside the cell, with potentially major implications ... […]
- Kidney cancer immunotherapy combo approved for NHS use in England on April 5, 2019 at 11:27 am
A combination of immunotherapy drugs will be made available to NHS patients with advanced and aggressive kidney cancer on the NHS in England. The decision to approve the treatment follows an ... […]
- Cancer Immunotherapy May Run Afoul of Exosomal Checkpoint Proteins on April 5, 2019 at 7:35 am
Checkpoint inhibition, a revolutionary cancer immunotherapy, works only in a minority of patients, and scientists want to know why it is resisted in the majority. At the UC San Francisco (UCSF), ... […]
via Bing News